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Abstract: This work compiles information on the principles of diagnostic immunochemical methods and 
the recent advances in this field. It presents an overview of modern techniques for the production of diag-
nostic antibodies, their modification with the aim of improving their diagnostic potency, the different types 
of immunochemical detection systems, and the increasing diagnostic applications for human health that 
include specific disease markers, individualized diagnosis of cancer subtypes, therapeutic and addictive 
drugs, food residues, and environmental contaminants. A special focus lies in novel developments of immu-
nosensor techniques, promising approaches to miniaturized detection units and the associated microfluidic 
systems. The trends towards high-throughput systems, multiplexed analysis, and miniaturization of the diag-
nostic tools are discussed. It is also made evident that progress in the last few years has largely relied on novel 
chemical approaches.
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1  Introduction
The first immunoassays were described in the late 1950s [1]. They were performed with radiolabels in an aqueous 
medium and called radioimmunoassays (RIAs). Shortly thereafter, modified techniques followed, such as the 
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enzyme-linked immunoassay (EIA) and the enzyme-linked immunosorbent assay (ELISA) (cf, [2]), immuno-
histochemical detection of molecules in tissues, and fluorescence-activated cell sorting (FACS), to name a few.
Today, immunochemical methods represent a core diagnostic technique that will be available for increas-
ing numbers of applications [2–6]. Research in immunodiagnostics relies heavily upon analytical chemistry 
and nanotechnology [7]. More than 500 000 antibodies are presently available on the market, with informa-
tion easily accessible through various online sources such as www.antibodypedia.com and www.antibodies-
online.com. The development of diagnostically useful antibodies is progressing rapidly, based on both the 
modification of existing methods and also entirely new approaches such as yeast display.
Two other forces are driving instrumental innovation. On the one hand, increasingly sophisticated high-
throughput diagnostic instruments that must be handled by trained experts are being developed for clinico-
chemical laboratories. On the other hand, there is just as strong effort to develop small devices that are easy 
to use at point-of-care [8].
The progress of biosensor and biorecognition research in the past 10 years has been accompanied by the 
development of novel immunosensor techniques [9] that use improved methods to attach antibody or antigen 
molecules to sensor surfaces of intelligent microfluidic systems with integrated detectors. This development 
has facilitated miniaturizing diagnostic tests, allowing parallel measurements of different biomarkers in a 
single run, and speeding up the diagnostic procedures, all of which in turn enabled high-throughput analysis 
at reduced cost. As a consequence, an increasing number of novel and improved diagnostic tools are avail-
able in clinical laboratories and expand into many other health-related areas such as environmental pollu-
tion monitoring and residue analysis.
2  Advances in generating diagnostic antibodies
2.1  The immune system and antibodies
The immune system is a highly complex network of cells, enzymes, mediators, and immunoglobulins that 
become activated when foreign substances and microorganisms enter the body. The resulting effect is to 
neutralize the internalized entity and thus protect the organism [10, 11]. For the immune defence of the func-
tioning organism, white blood cells and supporting enzyme systems (e.g., the complement system) are as 
crucial as immunoglobulins (i.e., antibodies). In immunoassays, antibodies are the basic recognition ele-
ments responsible for the capture of the desired analyte.
In the living vertebrate, internalized foreign macromolecules act as antigens and induce in the adap-
tive immune system selective production of immunoglobulins that are suitable to bind the antigen [10, 12]. 
The Y-shaped structures of the immunoglobulins are composed of the heavy and light chains. The ends of 
the arms carry two identical variable regions (Fv) that are responsible for antigen recognition, whereas the 
rod-like region containing constant sequences (Fc) is important for physiological functions of antibodies. 
Immunoglobulin G (IgG) is the most common, robust, and best-studied type of antibody but there are other 
immunoglobulins such as IgA, IgE, IgM, and IgD.
The variable region of each heavy and light chain has an antigen recognition site, consisting of three 
complementarity-determining regions (CDRs). These are variable peptide sequences, each with a highly spe-
cific spatial structure and chemical surface pattern. The six CDRs of each arm of an immunoglobulin mol-
ecule interact noncovalently with the epitope of the antigen.
2.2  Immunogenicity of large and small molecules
Immunization is the process whereby either a single or repeated exposure of an organism to a foreign biomol-
ecule induces in the organism a response that neutralizes the intruding agent. Similarly, immunogenicity is 
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the ability of a (usually foreign) substance that is introduced into an organism to induce an immune response, 
which includes the production of antibodies. Many types of large molecules, notably proteins and glycopro-
teins, have generally good immunogenicity in animals. In order to increase the production of antibodies, the 
substances are usually injected together with an adjuvant that is a mixture of biological and non-biological 
substances that enhance the attraction of cells of the immune system to the injection site and thereby enhance 
the immune reaction. After one or several injections, those B lymphocytes of the immune system that are 
genetically able to produce antibodies against the administered antigen will start to proliferate and become 
plasma cells. These plasma cells then release soluble antibodies into the blood. The affinity of an antibody to 
its antigen often improves in the course of a prolonged immune response. This is called affinity maturation.
In contrast to large foreign molecules, injection of foreign molecules of small size ( < 1500 Dalton), such 
as pharmaceutical drugs, does not generally lead to antibody formation [13]. However, such small molecules 
(haptens) may gain immunogenicity when they are covalently attached to a macromolecule [4, 14–16]. When 
an animal is immunized with such a protein-hapten construct, a certain fraction of the resulting antibodies 
will be directed against epitopes of the macromolecule and another variable fraction against bound hapten. 
Altogether, the raising and isolation of antibodies against small molecules is often very time-consuming and 
has not always been successful.
2.3  Techniques to produce diagnostic antibodies
Antibodies used for diagnostic purposes should exhibit several key features such as high-affinity and speci-
ficity for their antigen, good binding behaviour when coupled to surfaces or to amplifying systems, and sta-
bility. Antibodies with such features must be raised and tested before they can be used reliably in an assay.
Instead of using the whole antibody molecule, it is possible to employ antibody constructs for diagnos-
tic purposes. A precondition is that they possess the complementary binding region. A number of different 
types of fragments are routinely used today (Fig. 1). The newer approaches to antibody design often focus on 
smaller fragments, such as the antigen-binding fragment Fab or its dimer F(ab′)
2
. Small fragments with pre-
served variable regions often exhibit well-preserved antigen-binding behaviour. They may have advantages 
over whole antibody molecules, specifically in situations where diffusion in a matrix is important (e.g., in 
immunohistochemistry), or where a small mass is favourable to improve detection signals.
Thousands of different antibody molecules with a wide range of affinities to different antigens are present 
in the serum of healthy humans and mammals at rather constant total concentrations. But, when a specific 
Fc: constant fragment
F (ab´ )2, Fab´ , Fab: antigen binding fragments
Fv: variable fragment
scFv: single chain variable fragment
sd Ab: single domain antibody





















IgG antibodies have 2 antigen binding sites (left), but
schematic representations often show only 1 site (right)
Antigen
Antibody
Fig. 1 Immunoglobulin G and some of its fragments. Immunoglobulin G is composed of two heavy and two light chains. The 
variable regions carry the antigen-binding site, which recognizes the epitope of the antigen. The figure shows some of the frag-
ments that are used in the development of immunodiagnostic tests. The insert shows that though each IgG antibody can bind 
two antigen molecules, systematic drawings often depict only one binding.
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antigen exposure occurs, the resulting immune response selects high-affinity antibodies from immunoglobu-
lin structural libraries, thus enhancing the selective proliferation of the lymphocytes, which are genetically 
able to produce such antibodies (or T-cell receptors).
Different methods are available to produce selected antibodies for scientific and technical purposes 
(Fig. 2). The classical method of raising antibodies is the repeated injection of an antigen-preparation in 
animals. The immune system of the animal will respond by producing the different antibody isotypes (IgG, 
IgM, IgA, IgE, IgD) at various levels, but IgM and IgG are the most important for use in immunoassays. 
Normally, production of a number of antibody molecules with small differences in their peptide sequences 
in the variable region, able to react with one or more epitopes of the antigen, will be induced. Thus, raw 
immunoglobulin fractions isolated from immunized animals contain a mixture of related antigen-specific 
antibodies (polyclonal). They belong to different isotypes with partly overlapping binding behaviour toward 
the antigen. For immunochemical diagnosis, these polyclonal antibody mixtures can either be used as such, 
or they can be subfractionated to achieve better homogeneity of the purified antibody. An immunized animal 
can remain a source for antibody production during its lifetime. The raising of polyclonal antibodies is often 
time-consuming and, if not always in one animal species, may be successful in a different species.
Monoclonal antibodies differ from polyclonal antibodies in that each copy has an identical peptide 
sequence, and thus an identical antigen-binding site. Thus, each copy has the same affinity to the same 
epitope of the antigen. Techniques to raise monoclonal antibodies were first developed in the 1970s [17]. In 
the early form of monoclonal antibody production, antibody-producing B cells retrieved from the spleen of an 
immunized animal were fused with an immortal tumor cell line [18]. The resulting immortalized hybridoma 
cells were selectively cultured and allowed to proliferate and produce antibodies. All antibody molecules 
derived from a single parent cell are identical. Those hybridoma cells producing the most suitable antibody 
molecule were separated from other cells and allowed to proliferate on a larger scale where they produced the 
desired amount of monoclonal antibody. In its early development, this technique was labour-intensive, and 
although it has now been optimized, it has been largely displaced by methods that allow a higher-throughput 
production of antibodies.
Today, antibody-fragments can be produced on a large scale in a process called phage display [19, 20]. 
The process begins when mRNA molecules coding for antibodies or their variable fragments are isolated from 
B lymphocytes. The corresponding complementary DNA strands (cDNA) are generated and amplified in vitro. 
The cDNA is then integrated into the gene of a bacterial virus (phage) in a way that allows the expression of 
antibody fragments on the viral surface. This technique can be used to produce millions of different variable 
region fragments (each derived from a different B cell). Those phages producing scFv and Fab fragments 
that fit best to the antigen will be amplified. Yeast display [21] is a related but even more powerful technique, 
where antibody fragments are produced by yeast cells on a larger scale. However, one has to be aware that 
the microbial synthesis of immunoglobulins will lack posttranslational species-specific glycosylation, which 
may affect binding affinity.
Recently, interest has focused on antibodies formed by camelids. Camels, llamas, and related species 
naturally form a special type of heavy-chain antibody devoid of light chains, which is quite stable, easy to 













Immunogen/antigen Type of antibody Source
Fig. 2 Types of antibodies. Different methods for raising and constructing antibodies are available today. Depending on the 
sources, the products have different technical and chemical properties.
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material for diagnostic and therapeutic antibodies. There are also efforts to use antibodies from chickens [23, 
24] or to raise antibodies using plant viruses [25].
2.4  Raising antibodies against families of small molecules
Many natural and manmade substances are members of chemical families that share a common backbone 
but differ with regard to side chains or functional groups. Examples are steroid hormones and many pharma-
ceuticals and pesticides [14, 26]. For immunodetection of such chemical families, it would be favourable to 
have one test that measures the sum of all congeners (desirably in a single assay) and a second test that meas-
ures individual congeners. This requires availability of suitable antibodies. Antibodies against the common 
chemical group can be produced either by immunization of an animal with just the chemical backbone where 
the variable side groups have been split off or blocked, or by immunization of animals with a mixture of all 
congeners, in the hope that the affinities of the formed heterogenic antibodies will be adequate to measure 
the sum of all congeners. In contrast, to produce congener-specific antibodies, animals are immunized either 
with each of the purified congeners separately, or with modified congeners where the chemical-family-spe-
cific backbone has been blocked. In each case, the resultant antibodies must be tested for their specificity 
and cross-reactivity. Analytical results can be further optimized on the level of the assay system, for example, 
by capturing the new antibody either with the hapten used for immunization or with a modified hapten.
2.5  Advances in the chemical modification of diagnostic antibodies
Immunochemical assays today are characterized by multiple interactions between antibodies, antigens, and 
detection systems. A number of classical chemical methods exist that allow connection of a protein with other 
compounds. These include the use of carbodiimide, bromocyan, or hydrazide. In addition, immobilisation pro-
tocols using biomolecules to which immunoglobulins bind with high affinity have been developed. The best 
examples are protein A (from Staphylococcus aureus) and protein G (from Streptococcus sp.), both of bacterial 
origin, which are known for their ability to bind to the Fc region of IgG. ZZ protein is a synthetic Fc-region-bind-
ing domain, derived from protein A. Affinities differ, depending on the immunoglobulin isotype and animal 
species. These proteins are used for many purposes, such as detecting, cleaning, or attaching immunoglobulins.
In immunoassays, surfaces of assay devices may be pretreated with protein A or protein G so that an 
added antibody will be immobilized via its Fc region, with the distinct advantage of a freely accessible anti-
gen-binding site. Another protein with similar use is protein L (from Peptostreptococcus magnus), which 
binds to a domain of the antibody light-chain variable region.
Another standard procedure makes use of the high affinity of the streptavidin-biotin complex (SABC). 
Biotin readily binds to several Fc locations of antibody molecules without affecting the antigen-binding 
behaviour. Avidin, streptavidin, and NeutrAvidin proteins have the ability to bind up to four biotin molecules. 
These avidin molecules can be readily conjugated with detection enzymes or fluorochromes. When a biotin–
antibody conjugate comes in contact with streptavidin, a very strong noncovalent bond between biotin and 
streptavidin is formed. This chemical bridge allows attachment of an antibody to a surface or a detection 
device. It was also reported that NeutrAvidin had the highest degree of nonspecific adsorption to the surface, 
presumably due to its low carbohydrate content and near-neutral isoelectric point [27].
Epitope tagging is a comparatively new method. It uses the insertion of an artificial peptide sequence into 
a (primary) antibody molecule to create a selective recognition site for a secondary antibody that is directed 
against the primary antibody. Usually, a small peptide with a defined amino acid sequence is inserted into the 
antibody molecule. This sequence (e.g., six consecutive His residues) serves as an epitope for a tag-specific 
secondary antibody. This technique has dramatically expanded the possibilities for constructing amplifying 
systems on demand. Although genetic engineering is the most common method for introducing epitope tags 
into a protein, chemical methods are also in use.
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Another approach to introduce chemical reactivity into an antibody molecule is the attachment of reac-
tive groups to polysaccharide residues of the Fc fraction. When the movement of the Fc region is restricted by 
its surroundings, this may affect the stoichiometry and strength of the antibody-antigen binding [28]. In one 
study, a hapten linker increased sensitivity 100-fold [29].
3  Advances in immunoseparation
Many of the basic immunoseparation techniques were developed between about 50 and 100  years ago. 
These methods have since been continuously improved and diversified for specific applications. Some of the 
methods are basic components of immunodiagnostic tests and will therefore be described here.
3.1  Immunoprecipitation and particle aggregation
Each IgG antibody molecule has two identical binding sites for its antigen. At the same time, most antigen 
molecules have more than one epitope to which different polyclonal antibodies can bind. This is why mixing 
an antibody with its antigen leads to extensive crosslinking and visible precipitation of immune complexes if 
adequate concentration ratios prevail. In the immunoaggregation test the detecting antibody molecules are 
bound to the surfaces of suspended particles (e.g., latex). Addition of antigen then results in particle aggre-
gation and visible turbidity (Fig. 3) that can be quantified, for example, with light-scattering methods. This 
conventional method still has applications today [30–32], notably in the form of chromatin immunoprecipita-
tion (ChIP) [33].
3.2  Immunodiffusion
In the Ouchterlony immunodiffusion test, antigens are allowed to diffuse in a matrix such as agar-agar 
from an application point towards the diffusing antibody [34]. At the distance where antibodies and anti-
gens concentration reach equilibrium, the precipitating antigen–antibody complex forms. The precipitation 
line often has the form of a circular arc and can be evaluated with the naked eye. This and related simple 







Fig. 3 Latex agglutination assay. The latex agglutination assay is a classical immunochemical test. Addition of the antigen 
leads to crosslinking of the particles and visible turbidity. The relative concentrations of the reaction partners affect the result.
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3.3  Immunochromatography
In this approach, antigen is dissolved in a suitable aqueous solution and subjected to paper, thin-layer or 
column chromatography. The antigen moves towards an antibody layer where an antigen–antibody complex 
is formed. Although this is a comparatively simple and well-established technique [35], the thin-layer 
approach has turned out to be a platform of outstanding value in immunodiagnostics. In fact, this approach 
is one of the leading separation principles in immunodiagnostic assays today, where it is called a lateral-flow 
immunochromatographic assay (see below).
3.4  Immunoaffinity separation
This technique exploits the strong binding force between antibody and antigen with the aim of separating 
and purifying one of the reaction partners [36]. In one variant of the immunoaffinity technique, the antigen 
is chemically attached to a suitable solid matrix such as column-chromatography material. When a biologi-
cal fluid containing the antibody is added, the antibody will be fixed by the matrix-bound antigen, whereas 
impurities will be washed out. An elution buffer then liberates the purified antibody from the antigen.
3.5  Immunoelectrophoresis
Immunoelectrophoresis [37] is a method by which proteins are separated in an electric field on a suitable 
matrix such as agarose or polyacrylamide gel and then identified on that matrix by immunoreaction with their 
recognizing antibodies. Electrophoresis can be done with native proteins that have their epitopes conserved, 
or it can be done with proteins that have lost their tertiary structure, for example, in a sodium dodecylsulfate 
(SDS)-containing buffer. In the latter case, the tertiary structure of the separated proteins must be reconsti-
tuted before immunodetection. This occurs by allowing the protein to diffuse from the SDS-containing matrix 
into a fresh matrix (immunoblotting) containing a reconstitution buffer, sometimes with the accelerating 
aid of an electric field (electroblotting). The transferred proteins are then identified with antibodies.
3.6  Fluorescence-activated cell sorting (FACS) separation and detection
FACS is a technique that allows separation of cells according to size and cell-specific molecular markers, and 
is also increasingly used to separate coated particles. FACS is a special form of flow cytometry (FCM) and will 
be described in connection with FCM below.
4  Architecture of immunoassays
Hundreds of different variants of immunoassays are in use. They are the result of optimization for individual 
antigen–antibody interactions. However, there are a couple of construction principles that can be considered 
as a general skeleton of immunoassays.
The centres of interest are primary antibodies and their specific binding to the antigen. The molecular 
scaffolds around this reaction have the purpose of stabilizing the reaction and measuring its products with 
high sensitivity and accuracy. Parts of the scaffold may include proteins A or G, the SABC method (described 
above), or related capture methods. Secondary antibodies that bind to the Fc part of primary antibodies are 
often used. In order to work, secondary antibodies must be species- and isotype-specific to the primary anti-
body. The same is true for tertiary antibodies and their affinity to secondary antibodies. The following types 
of antibodies can be differentiated:
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Primary antibody Binds the antigen
Secondary antibody Binds to primary antibody, functions as detection or amplifying antibody
Tertiary antibody Binds to secondary antibody, often functions as detection antibody
Capture antibody Anchors to a solid surface, binds to the antigen
Coating antibody Coats a surface, often a capture antibody
Detection antibody Carries a reporter system
The arrangement of the construction elements differs according to the type of assay. Here we describe 
some common assay formats:
4.1  Immunosorbent and immunochromatographic assay
The immunosorbent assay [2, 6] is one of the best-known immunoassays (Fig. 4). The term “sorbent” means 
that the primary reactant of the assay is firmly adsorbed to a suitable surface. The chemical reaction is built 
up on the attached primary molecule, usually in a microwell (also called a microtiter) plate with a suitable 
surface such as polystyrol, or in some cases on particles [38]. The detection system is often an enzyme reac-
tion (enzyme-linked immunosorbent assay  = ELISA) or a fluorescent signal (fluorescence-linked immuno-
sorbent assay  = FLISA), but many other systems are also in use.
Lateral flow assay or immunochromatographic assay does not fix the reaction to a surface but allows 
the analyte and part of the diagnostic molecule(s) to migrate on paper or other thin-layer chromatography 
material [39]. A sample of the analyte, such as urine or blood, is applied to the starting point of the diagnostic 
device (see Fig. 5). The fluid is allowed to migrate in one direction. On its way, the fluid mobilizes antibody-
coated particles that are integrated into the matrix. While migrating, antigen can bind to its corresponding 
antibody on the particle surface. The antigen-carrying particles are fixed in a detection zone, where they 
form a coloured stripe that can be evaluated with the naked eye. Non-antigen-carrying particles move on to 































Fig. 4 ELISA; examples for different formats. ELISA and related assays can be used to measure either antigens or antibodies. 
The figure shows some of the common assay formats. “Direct” means that there is no secondary antibody or other secondary 
detection system. “Indirect” means that there is a secondary detection system. The “competitive” tests measure the result of 
multiple equilibria to assess the concentration of the analyte.
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test, which simply differentiates between a positive and negative result for human chorionic gonadotropin in 
urine. Dipstick immunoassays [39] use the immunochromatography principle for on-site analysis.
4.2  Competitive and noncompetitive assays
Immunoassays can be used for the detection of both antigens and antibodies (Fig. 4). In the non-competi-
tive assay, the test surface, such as a microwell plate, is coated with the primary (capture) agent. The biologi-
cal material containing the analyte (antigen or antibody) is added and allowed to bind to the capture agent. 
If the analyte has been labelled, it can be detected directly (direct assay). Otherwise, detection requires the 
use of additional detection systems (indirect assay) such as an additional primary antibody that binds to a 
different epitope of the antigen (sandwich system) or additional augmentation systems such as secondary 
and tertiary antibodies.
A competitive assay (also called an inhibition assay) is applied, for example, when the antigen has 
only a single epitope, or if only a single antibody is available for binding to the antigen. The primary agent 
is coated on the microplate surface, and a defined amount of labelled analyte is added. Then the biological 
material containing the investigated analyte is added. This displaces labelled analyte from the antibody-
binding site. The equilibrium concentration of the labelled analyte in the supernatant is then proportional 
to the analyte concentration in the biological sample, whereas the amount of plate-bound label is inversely 
related to the concentration. The competitive antigen can be either identical to, or just related to, the antigen 
used for raising the antibody; in the latter case it is referred to as a “heterologous hapten”.
Immunoassays may be homogeneous or heterogeneous. In a homogeneous assay the reagents are 
in the liquid phase. In a heterogeneous assay the primary component is attached to a solid phase and the 
reaction occurs in an aqueous phase. The latter is presently the more common form for ELISAs and related 
systems.
5  Detection principles
Today, an increasingly large number of detection principles are available for immunoassays. Although the “E” 














Mobile, labeled primary antibody




Fig. 5 Schematic drawing of an immunochromatographic assay. The steps of the immunochromatographic assay, also called 
lateral flow test, are shown. After addition of the sample fluid containing the antigen, the fluid migrates through three zones, 
where different reactions take place.
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some authors today use the terms EIA or ELISA as “exchangeable”, and even for immunoassays using other 
detection systems. One can differentiate between label-free assays and assays requiring labelled molecules. 
The latter have the disadvantage that labelling is an extra step, which has the risk of affecting the antibody–
antigen reactivity. Labelling methods will be described in the section on immunosensors.
5.1  Detection with labels
Radiolabel. The radioimmunoassay (RIA) was the first elaborate immunoassay technique [1]. Originally it 
was performed in solution using precipitation methods. Although it is very sensitive and fast, it has gone out 
of common use, partly because of the safety problems associated with radiolabelled compounds. But in some 
tests (e.g., the study of thyroid hormone receptors) it can provide superior sensitivity when radiolabels with 
high specific radioactivity and high decay energy are used.
Enzyme label. Enzyme immunoassay (EIA) is an umbrella term for enzyme-linked detection. The rate 
of product formation is proportional to the analyte concentration in the sample and is usually detected by 
colour change. EIA can be combined with various separation and capture techniques. It can be used to detect 
antigen or antibody. It was originally performed as a homogeneous test. The enzyme-linked immunosorbent 
assay (ELISA) is a form of EIA where the scaffold is a solid surface upon which the analytical components are 
built, with an enzyme reaction as the final detector. It is a heterogeneous test.
Fluorescence label. The increasing variety and availability of stable fluorophores, and the advances in 
coupling them to a large number of functional groups, have enabled for fluorescence detection to become a 
leading method in immunoassays [40]. This has been favoured by recent advances in miniaturization of the 
equipment and the commercial availability of easy-to-use building blocks. The net result is a significant advan-
tage over many other detection systems. Several types of fluorophore-reporter molecules can simultaneously 
be measured in parallel with good precision and sensitivity, allowing the user to make multiplexed analysis.
5.2  Label-free detection
This type of detection has the advantage that it does not require any labelling of molecules and thus avoids 
the extra effort for labelling and the danger of label-associated artefacts. Most of the current label-free detec-
tion techniques rely on detecting changes in refractive index, mass, heat, or electrical current when the target 
binds to its recognition element.
Surface plasmon resonance (SPR). An antibody is attached to a gold-coated surface. When antigen is 
added, the light emission behaviour of the gold surface will change in proportion to the mass increase of the 
antibody–antigen complex on the surface. This is a very powerful method [41], allowing for both the detec-
tion of antigen–antibody binding and also for studying binding kinetics and thermodynamics. More label-
free techniques will be described in Section 6 (Immunosensors).
5.3  Amplified detection with label
5.3.1  Immuno-polymerase chain reaction (IPCR)
IPCR makes use of the fact that nucleic acids can be determined at much lower concentrations than proteins. 
IPCR is an extremely sensitive detection method, combining the specificity of antibody detection and the 
sensitivity of PCR [42, 43]. Here, the secondary antibody is connected to a marker DNA. The antigen–antibody 
binding induces a polymerase chain reaction, producing amplicons, which are detected. This technique can 
increase the sensitivity of immunoassays 1000-fold or more. By using several different marker DNAs, several 
antigens can be detected in a single assay, thus allowing multiplexed detection.
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5.3.2  Catalyzed signal amplification (CSA)
This is another example of a complex detection system that allows staining with high sensitivity in immu-
nohistochemistry [44]. In a first step, the antigen is labelled with a primary antibody, followed by a perox-
idase-labelled secondary antibody. Then biotin-tyramide is added, oxidized by a peroxidase, and thereby 
precipitated near the antigen. A streptavidin-peroxidase conjugate is then added and binds to the precipi-
tated biotin. This increases the peroxidase signal many fold. This method has several variations.
5.3.3  Luminescent oxygen channelling immunoassay (LOCI)
Various detection methods rely on luminescence [45], either for measuring cell signals, improving sensitivity, 
or reducing the workload of an immunoassay. LOCI is one of the well-known applications [46] (Fig. 6).
6  Immunosensors
6.1  Sensors
Much current chemical research is dedicated to the miniaturization of immunochemical detection systems 
using sensors. From a diagnostics point of view, a sensor is a small platform capable of measuring changes 
in a particular physical quantity, and then converting it into a signal. The basic prerequisite is that it can 
selectively measure molecules without influencing their properties. Sometimes a sensor is used to study 
the thermodynamics and kinetics of a chemical reaction [47, 48]. A sensor that can measure antigens with 
the use of antibodies, or vice versa, is called an immunosensor. Several very good reviews dealing with 
various measuring principles and advances in immunosensor design have appeared in the past few years, 
covering “lab-on-a-chip” technology [49, 50], the use of nanoparticles [51–53], wireless sensor networks 
[54], impedimetric principles [55], and point-of-care diagnostics platforms [56], among other topics. The 
major challenges in the design of an immunosensor are related to the need for miniaturization and for 
complex on-site analysis in medical diagnostics and other fields of human safety. A sensor is required to 
measure accurately the target analyte, typically present in very low concentrations in complex media, 
in the lowest possible volume and with minimum user manipulation. Therefore, the design and manu-











































Fig. 6 Luminescent oxygen channeling immunoassay. This is a very elaborate assay which includes different particles and 
reagents in addition to the analyte. It can yield high sensitivity. The final detection is by light measurement.
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apply knowledge from both life sciences and engineering. The components of an immunosensor are now 
increasingly related to chips used in computers, digital cameras, mobile phones, and inkjet printers. This 
opens up the possibility of fabricating immunosensors on a large scale with available chip technologies, 
which will reduce the price.
6.2  Advances in the surface chemistry of immunosensors
The detection principle of an immunosensor relies on the specific interaction between the desired analyte 
(antibody, nucleic acid, metabolite, etc.) and its recognition element, which is typically immobilized on a 
surface. To maximize the signal from the binding event, the capturing molecules must be immobilized in 
a mode that will enable them to retain their activity. This is one of the most critical parts of the biosen-
sor, as the mode of immobilization will have a crucial effect on the sensitivity and accuracy of the device 
(Fig. 7). Interestingly, the recent advances in polymer science are shifting the trends in the development of 
immunosensors towards more disposable platforms. The real driving force is the need to develop inexpensive 
and disposable sensor substrates, with excellent physical properties, good chemical resistance, and ease 
of fabrication. New technological processes enabled the manufacture of the substrates with incorporated 
microstructures to accommodate various functional elements to pre-condition and handle a biosample, for 
example, metering, mixing, dilution or concentration in an appropriate buffered solution, plasma extraction, 
filtration, purification, and the interaction with other bulk or surface-confined reagents [57–59]. For these 
reasons, the trend is that new polymers and plastics are replacing more traditional surface materials such as 
glass, gold, and silica.
Fuelled by the increased interest in biomedical diagnostics, a number of scientific articles, reviews, and 
books dealing with useful immobilization strategies have appeared in the past few years [60–65]. They typi-
cally appraise methods mainly based on physical, covalent, and bioaffinity mechanisms of immobilization. 
The motivation behind these methods is to ensure the most favourable orientation of the immobilized bio-
molecules, in which the antigen-binding site is oriented away from the surface itself.
In general, the choice of a suitable immobilization strategy is determined by the physicochemical proper-
ties of both the surface and the biomolecules.
For example, Hu et al. [66] presented an interesting approach for covalent and oriented immobilization of 
scFv antibody fragments via an engineered glycan moiety. Their strategy was to immobilize the glycosylated 
scFvs at salt concentrations that precluded nonspecific adsorption of unglycosylated molecules, and the cova-
lently attached antibody fragments then exhibited 4-fold higher functional activity than ionically adsorbed 
scFvs. Similarly, Walper and coauthors [67] compared the effect of an oriented immobilization method for sin-
gle-domain antibodies (sdAbs). The format that provided the highest density of active molecules by at least 
a factor of two was an sdAb–streptavidin core tetramer. This was followed by the sdAb-alkaline phosphatase 
and then the site-specifically biotinylated monomer. The poorest performing immobilization methods were 
Fig. 7 Possible orientations of IgG on a surface. The schematic drawing shows that some of the orientations will lead to a 
partial or total blocking of the antigen-binding sites of the antibody. Therefore, it is important to be aware of this problem when 
designing an assay.
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the two most common, direct covalent attachment and the randomly biotinylated sdAb attached via NeutrA-
vidin. Importantly, the oriented immobilization method also translated into improvements in limit of detec-
tion using a bead-based system. The sdAb–streptavidin core provided more than a 100-fold improvement in 
the limit of detection.
The differences between the immobilization modes and surface orientation of the full-size antibodies 
and antibody fragments were assessed by Balevicius et al. [68]. Total internal reflection ellipsometry (TIRE), 
a surface-specific technique, was used to investigate biological recognition layers of immunosensors. The 
data analysis showed that the immobilized active antibody fragments can specifically interact with a 2.5-
times greater amount of antigen when compared to a randomly oriented layer of whole antibody. However, 
a uniform orientation of capture molecules does not necessarily translate into high-affinity interactions. 
Trilling et al. [69] used variable domains of llama heavy-chain antibodies (VHHs) as capture molecules to 
investigate which analyte properties contribute to sensitivity by orientation. SPR chips with randomly immo-
bilized biotinylated VHHs were compared to streptavidin-coated SPR chips, on which similar quantities of 
oriented biotinylated VHHs were noncovalently immobilized. The authors suggested that orientation of the 
capture molecule hardly affects high-affinity interactions. Nonetheless, it leads to strong improvements in 
sensitivity for lower-affinity interactions.
Alternatively, metal ion affinity methods have been widely used to investigate the oriented immobiliza-
tion of His-tagged proteins onto immunosensor chips covered with a functional stromatoid chelator, such 
as iminodiacetic acid (IDA) or nitrilotriacetic acid (NTA), via covalently bound films, polymer films, or both. 
Yang [70] and his colleagues reported on a strategy for oriented immobilization of functionally intact IgG 
on a polystyrene microwell plate via (IDA)–Ni2+ and ZZ–His protein interaction. The authors immobilized a 
ZZ–EAP (Escherichia coli alkaline phosphatase)–His fusion protein, which exhibited Fc binding, His tag, and 
intrinsic alkaline phosphatase activities. The authors analyzed the interaction between rabbit IgG anti-horse-
radish peroxidase (anti-HRP) and its binding partner HRP to investigate the specificity and efficacy of their 
method. The His-tag-assisted method showed an enhanced signal, a 10-fold higher sensitivity, and a wider 
linear range. As an interesting alternative, the His-tagged binding surface layer can also be constructed by 
peptide self-assembled monolayer (SAM) as demonstrated by Bolduc and co-workers [71]. Significant reduc-
tion of nonspecific adsorption of non-analyte constituents of crude serum was reported using penta- and 
hexa-peptide monolayers.
Oriented covalent immobilization of antibodies onto heterofunctional metal chelate-glyoxyl supports 
(Ag–Cu2+/G) was also the subject of a study by Batalla [72]. The immobilization of IgGs takes place in two steps: 
(i) the antibodies are conjugated to the support via His–metal coordination bonds, and (ii) their incubation 
under alkaline conditions then promotes an intramolecular covalent attachment between lysine residues at 
the Fc region and glyoxyl groups on the support surface. The optimal antibody distribution was achieved 
when these proteins were slowly immobilized on Ag–Cu2+/G in the presence of imidazole. This bioconjugate 
was able to bind up to 1.5 mol of antigen per mole of antibody, only 1.3-fold less than the antibody in solu-
tion. Although their approach is more relevant to immunoaffinity chromatography, the resulting fairly inert 
solid surfaces and the optimally bound antibody bioconjugates showed high specificity towards the target 
antigens with reduced nonspecific binding of any other proteins.
While the simplest method of immobilization of the biorecognition elements on any surface is physical 
adsorption, most of the new materials are not always suitable for physical attachment of typically hydrophilic 
molecules to the often-hydrophobic plastic surfaces [73, 74]. The noncovalent binding mechanism in the 
physical adsorption process not only governs the random orientation of the captured proteins but also their 
denaturation on almost every type of material [75]. However, Zhao et al. [76] investigated the specific recogni-
tion between physically adsorbed and covalently captured monoclonal antibody to prostate-specific antigen 
(anti-hPSA) and its antigen (hPSA) for applications in prostate cancer diagnostics. In their study, the authors 
used spectroscopic ellipsometry and neutron reflection to investigate how solution pH, salt concentration, 
and surface chemistry affect antibody adsorption and subsequent antigen binding. The authors concluded 
that on all surfaces studied, the antibody predominantly adopted a “flat on” orientation. Perhaps contrary 
to general belief, the major finding was that a carefully executed antibody immobilization via appropriate 
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Fig. 8 Cantilever, schematic drawing. The cantilever is a micromechanical device. When a reaction takes place on the lever, 
leading to a mass increase, a deflection occurs, which can be measured with an optical device.
physical adsorption can actually replace elaborate interfacial molecular engineering involving complex 
covalent attachments. Similar results were previously reported by the group of Williams [77], who studied 
interfacial adsorption of a mouse monoclonal antibody (type 1 IgG, anti-βhCG) at the hydrophilic silicon 
oxide/water interface.
Overall, the new and emerging polymeric, disposable materials used for sensor substrates introduce 
some technological advantages in the production of immunosensors, such as ease of fabrication, low cost, 
machinability, and facile large-scale production. However, while the specific chemical nature of such materi-
als can sometimes be seen as an advantage, it also introduces a specific feature and an undesired challenge 
in the limited choice of the surface chemistry used for the chemical activation of the plastic sensor substrates.
6.3  Detection systems of sensors
In general, a detection system can be either label-free or labelled. Label-free systems have the advantage 
that the additional second step of introducing a labelled reporter molecule or an enzyme is not required. In 
label-free systems the sensor’s detection system measures reaction-related physicochemical changes on the 
sensor surface. The label-free transducer principles are typically based on a variety of responses, including 
increase of mass-induced mechanical deflection (cantilever) [78, 79] shown in Fig. 8, mass spectrometry [80], 
mass-induced change of gold/silver surface light reflection surface plasmon resonance [81], electrical poten-
tial changes [82, 83], change of the inner heat (calorimetry) [84], acoustic or surface acoustic wave detection 
[85], surface-enhanced Raman scattering [86], and piezoelectric or piezoresistive platforms [87, 88], among 
others (Table 1). Label-free detection methods have been used primarily for in-depth characterization of bio-
molecule interactions. There are often misconceptions about the accessibility of these platforms, since they 
usually require specialized training. A new wave of more cost-effective, robust, and accessible platforms has 
appeared. One of the recent emerging technologies is the dotLab System, which uses diffractive optics system 
(dot) to detect biomolecular interactions and can be used for a variety of applications in the study of a spec-
trum of biologically relevant analytes, including proteins, DNA, and even microorganisms [89].
Alternatives to label-free approaches are detection systems requiring an optically visible or electrochemi-
cally responsive label in order to visualize the binding event. Owing to their simplicity, high potential for 
miniaturization, and relative ease of operation, these methods are very popular despite the obvious potential 
disadvantage that one or more additional chemical steps are required, each with a risk of failure.
In ELISA and FLISA, the classical labels are enzymes or fluorescent dyes. In both cases, it is essential 
to maximize the signal-to-noise ratio to achieve clinically relevant sensitivity and limits of detection in the 
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immunoassay devices [90]. Simple assay designs involve first capturing an antigen onto a surface using one 
antibody, then measuring the surface concentration by visualizing the captured antigen through its reaction 
with a second, labelled antibody. Recently, organic dyes were replaced with nanoparticles (NPs), doped with 
tens of thousands of dyes, thus providing an intense signal. Fluorescent NPs are useful as labels since they 
can be measured directly, without the need for any amplification step [52, 91, 92]. NP labels can, however, 
suffer from disadvantages in comparison with simple molecular labels, most notably effects due to particle 
aggregation [93] and the related effect of nonspecific binding [94] to the capture surface. The benefits of using 
NPs can only be realized if they are efficiently coated with detection antibody and the fraction of the coupled 
antibody that is in fact active or available for reaction with antigen [95] is sufficiently large.
Lin et al. [96] recently presented variations of ELISA by using enzymes that release oxygen radicals and 
thus initiate oxygen-triggered fluorescence reactions (Fig. 6). These can be measured with a photomultiplier 
or with a small and comparatively inexpensive light-sensitive CMOS chip that is also used in digital cameras.
MacCraith and Ruckstuhl were pioneers in concepts of efficient collection of the fluorescent light emitted 
by the reporting molecules in assays. They demonstrated the advantages of collecting the emitted light under 
the supercritical angle fluorescence (SAF) in biomedical diagnostics [97, 98] and in optical imaging [99]. This 
new technology enables monitoring of analyte binding in real time with high discrimination relative to back-
ground fluorescence. The SAF technology is an inexpensive and sensitive platform adaptable to scanners and 
multiwell plates, and it seems to have a great potential for replacing the work-intensive and time-consuming 
ELISA.
Electrochemical methods are also increasingly applied to immunoassays, because they overcome prob-
lems associated with other modes of detection. In particular, when compared to conventional immunoas-
says, electrochemical immunosensors show versatility, reliability, and fast analysis time. A review by Laschi 
[100] presents some interesting examples of immunochemical assay developed using magnetic beads as a 
solid phase coupled with electrochemical detection techniques, in particular, using electrochemical arrays 
as transducers.
6.4  Microfluidic systems
Microfluidic systems tailored for analyte separation and detection have attracted increasing research activity 
over the past decades. In particular, the prospect of integrating all steps from sample preparation and reagent 
storage to assay readout in a single microfluidic device bears great promise to leverage next-generation diag-
nostic products. Modern sensors are the core part of microdevices [101]. Currently, the standard control of the 
reagent flow is done by intelligent microfluidic systems with micropumps and valves. However, the need for 
novel, low-resource fabrication and assembly methods for creating disposable detectors leads to the devel-
opment of alternative microfluidics concepts such as hybrid paper-polymer devices [102], centrifugal micro-
Table 1 Novel immunosensor detection systems (examples). The table depicts some of the developments, which are aimed at 
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fluidics platforms [103], and regeneration-free immunosensors [104]. The recent surge in the development of 
microfluidics systems was fuelled by research advances in polymer science. In particular, the availability and 
the great choice of new classes of polymers and co-polymers sparked an enormous interest from scientists to 
use them as disposable substrates for diagnostic devices [105]. These materials have been engineered to meet 
key criteria such as low autofluorescence, ease of fabrication, and manipulation. Importantly for microfluid-
ics development, they also have excellent mouldability and good machinability to form complex microfluidic 
features such as channels [106, 107], valves [108], and other features enabling samples to be preprocessed 
with relative ease: dilution or concentration in an appropriate buffered solution, filtration, purification, and 
the interaction with other bulk or surface-confined reagents.
The new, state-of-the-art microfluidics systems often need to measure in less than 1 µL of sample volume, 
with the analyte concentration in pmol/L range and with minimum user manipulation. While the prospect 
that even a very small sample of blood or of biological material is sufficient to make many different analyses 
could be seen as a distinct advantage, it also bears some technological challenges for microfluidics systems. 
For example, because the concentration of the target molecule(s) is often very low, it is critical to maintain 
that concentration while delivering the analyte-containing fluid through the microfluidic preprocessing fea-
tures to the active assay area of the chip substrate. Antibodies are common examples of analytes in diagnostic 
devices, and can randomly adsorb onto the surface of the plastic substrate [109]. Therefore, their final con-
centration over the detection area can be quite different from the original crude sample, which can contribute 
to false negatives or inaccurate quantitation.
Though promising, there are nonetheless major challenges with which the new microfluidics systems 
will have to cope. Some are related to the need for miniaturization and trends for multiplexing [110–112], 
which means that the parallel measurements of different analytes are performed in one set and with the 
same fluidic system. These two specific requirements must be addressed along with the basic requirement 
for minimum user manipulation to ensure high precision and accuracy [113] of the immunosensor. However, 
this means that the space-demanding microfluidics features such as sample preprocessing, dilution, reagent 
storage, purification, and the actual sensor area must all be incorporated into one single substrate. The factor 
of the “small footprint” or limited “real estate” on most of the microfluidics systems that operate along a 
single axis or plane will need to be reconsidered, particularly in those that are aimed for production of single-
use, point-of-care diagnostics devices.
6.5  Role of chip technology
The emerging market of modern chip technology of mobile phones, cameras, and inkjet printers, and their 
use in the health sector, is rapidly expanding. An appealing advantage is realized in telemedicine, with 
connection to even the remotest areas of the world. Some recent logical innovations include saving and 
subsequently distributing diagnostic images over the mobile network for knowledge sharing, feedback or 
quality control, integration of the mobile phone’s images with bioassay microchips, or simple biomedical 
optical analyses using available photodiodes or CMOS sensors.
Wang et al. reported on a simple and inexpensive microchip ELISA-based detection module that employs 
a portable detection system, i.e., a cell phone/charge-coupled device (CCD) to quantify an ovarian cancer 
biomarker, HE4, in urine. In their study, the sensitivity of microchip ELISA coupled with a cell phone or a CCD 
was 89.5 % at a specificity of 90 %, which compared favorably with that obtained in a previous study using 
conventional microplate ELISA [114].
Recently, Balsam et al. exploited the possibility of biomedical optical analysis using a low-sensitivity 
webcam. They captured hundreds of low-sensitivity images using a webcam in video mode, as opposed to 
a single image typically used in a cooled CCD. Then they used a computational approach consisting of an 
image-stacking algorithm to remove the noise by combining all of the images into a single image [115].
Tuijn and co-workers have performed feasibility studies in Uganda of using mobile phones for capturing 
microscopy images and transferring these to a central database for assessment, feedback, and educational 
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purposes. Clear images were captured using mobile phone cameras of from 2 megapixels (MP) up to 5 MP. 
Images were sent by mobile Internet to a website where they were visualized and feedback could be provided 
to the sender by means of text messaging [116].
Pioneering studies such as those mentioned here are prime examples of where connecting mobile tech-
nology to diagnosis has a considerable potential to improve diagnostic services and to bring current biomedi-
cal diagnostic approaches to the majority of the world’s population in resource-poor settings with remote 
clinical centres. It is anticipated that at the current pace of integration of mobile technology and immunosen-
sors, we are close to products that will reach the stage of point-of-care field-testing. This is particularly true 
for many biomedical devices based on optical detection ranging from microarray analysis to FCM.
7  Immunochemical visualization of tissues and cells
7.1  Immunohistochemistry with tissue slices
Two aspects can be distinguished in cell biology: structure and function. Histochemistry is a method to detect 
and localize specific structures in tissues, cells, or subcellular specimens. In its traditional format, it makes 
use of chemical affinities to biological molecules of dyes or other reporters, or visualizes enzyme activities. It 
is often performed on tissues that have been fixed with substances like formaldehyde, in order to arrest living 
processes and to “freeze” the tissue in its original structure. Immunohistochemistry uses antibodies to detect 
specific molecules and subcellular structures, with which they are associated. Thin tissue slices are cut and 
incubated with a solution containing the antibody. The attachment sites of the antibody are visualized with 
an enzyme reaction or with a fluorescent label. Hundreds of fluorophores are available today, which differ 
with regard to their affinities to biomolecules, their stability, and their excitation and emission wavelengths. 
The slices are then analyzed under a (fluorescence) microscope to detect the localization of colour or fluores-
cence in the tissue.
Immunohistochemistry is a leading method in cell biology [117]. It provides information about locali-
zations and dynamics of cellular components. It is an important tool of inter- and post-surgical diagnosis, 
allowing the pathologist to provide a rapid result concerning type and extent of pathologic structures in a 
patient’s tissue. In industrial toxicology there is a need for histological examinations of virtually all organs 
that must be tested for pathologic parameters. This has led to the development of a highly standardized and 
sometimes automated immunohistochemical methodology [118]. Organ slices are cut by a slicing machine, 
automatically incubated with the antibody-containing reagent, and transferred to the microscope where the 
histological picture is automatically evaluated with specific software. The procedure provides the required 
information about the normal histology and toxicant-induced pathologic changes.
There are cases where antigens in the tissue are masked and thus inaccessible to diagnostic antibodies. 
In such situations, heat- or proteolysis-induced epitope retrieval can be applied to improve the signal [119, 
120].
7.2  Immunohistochemistry of suspended cells
Related techniques can be performed in single-cell suspensions, such as living white blood cells. Depending 
on the technique, the cells may be permeabilized to allow entry of a fluorescence-labelled antibody, which 
binds to structures carrying the antigen. At the end of incubation, the fluorescence emission of each cell 
is recorded. Use of more than one antibody, each carrying a different fluorochrome, enables simultaneous 
detection of multiple cellular structures and can provide information on how they interact. High-throughput 
automated analysis can be achieved using microwell plates, for example, with 384 or more wells [121]. Here, 
numbers and intensities of fluorescent areas can be analyzed with a modern fluorescence plate reader.
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7.3  Immuno-electron microscopy
Immuno-electron microscopy is used to study the presence of the antigen within the ultrastructure of a 
tissue. After tissue fixation and embedding, ultrathin tissue slides are made and incubated with gold-colloid 
labelled antibody. Under the electron microscope, the gold particles are visualized as round, electron-dense 
spots [122, 123].
7.4  Enzyme-linked immunosorbent assay (ELISPOT)
ELISPOT visualizes proteins, which have been released by living cells in vitro. It is often used to detect anti-
gen-specific T lymphocytes, as they secrete cytokines upon specific stimulation. Practically, microplate wells 
are treated to attach a capture antibody on the solid well surface. Cells of interest are added on top and stimu-
lated so that they release specific proteins (e.g., a cytokine). Released molecules are captured by the immo-
bilized antibody. After a wash, a detection antibody is added. When the microwell plates are observed from 
above, the areas around those cells that have released the specific cytokine, can be visualized as colour spots 
(Fig. 9). The method has a unique strength for T-cell diagnostics [124]. It has been used for interferon gamma 
measurements in connection with transplantations for more than 20 years [125] and is used for measuring 
human immune responses to vaccines [126].
7.5  Lymphocyte transformation test (LTT)
In allergology, it is possible to differentiate between four different allergic mechanisms. A major difference 
is between allergy type 1, which is mediated by an IgE antibody, and allergy type 4, which is mediated by the 
T-cell receptor (TCR) molecules of T cells. The IgE molecules of type 1 allergy can be measured reliably with 
ELISA. But the detection of a type 4 allergy is much more elaborate. It can be done with the LTT, which meas-
ures the reactivity of T cells that possess the proper TCR for an allergen. When stimulating a larger number 
of suspended living T cells with the appropriate antigen, those (few) cells that carry the TCR molecules spe-
cific for the antigen will transform and proliferate. Proliferation can be measured as an increase of the DNA 
content during a several-day incubation (Fig. 10). Increased proliferation compared to control suggests that 
the blood contains T lymphocytes that are reactive to the antigen and may be the cause of a type 4 allergy. 
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Fig. 9 Visualization of cytokine releasing cells with ELISPOT. Enzyme-linked immuno spot assay (ELISPOT) is a technique that 
allows one to study in a cell mixture those cells that produce and release specific antigens (e.g., cytokines) after a stimulus. The 
cells are seeded on antibody-treated culture dishes. The antibody captures antigens that are released by the cells. A detection 
system allows the areas of releasing cells to be localized.
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Although the LTT (also called lymphocyte proliferation test) does not employ antibodies, it is a common 
immunological test for the diagnosis of metal and drug allergies [127].
7.6  Detection of cell types by flow cytometry (FCM)
FCM is classically used to study the numbers of lymphocytes and other leukocytes in the blood. These cell 
types and their subtypes carry characteristic surface proteins called cluster of differentiation (CD) antigens. 
Antibodies to CD antigens, labelled with different fluorochromes, are added to the cell suspension. Each 
of them binds to its respective surface protein and thereby differentially labels a specific cell type. The cell 
mixture is then allowed to flow cell-by-cell through a capillary system and its optical detection unit. The fluo-
rophores attached on each cell are excited by lasers of defined wavelengths, and the fluorescence emission 
is measured at two angles (Fig. 11). This allows characterization of each cell according to size and surface 
markers. Microspheric beads of defined size are used to calibrate the absolute numbers and sizes of cells.
Although originally developed for counting immune cells in the blood (e.g., in connection with leuke-
mia), FCM is now also applied to study other samples, such as single-cell suspensions which have been pre-
pared from organs [128, 129], bacteria, organelles, and bead-attached proteins. With three lasers for excitation 
and some 10 fluorescence channels plus 2 light-scattering channels in advanced high-end devices, more than 
100 parameters can be differentiated in a single run. Depending on cell type and conditions, between 1000 
and 50 000 cells or microspheres can be measured per second. This allows the detailed sub-differentiation 
of cell types that were previously considered to be identical, but can now be differentiated due to the avail-
ability of antibodies to many antigens on the cell surface. This enormous success in multiplexing has turned 
the method into a very powerful technique in clinical diagnostics (e.g., subtyping of leukemias) and research. 
However, it should be noted that such methods produce a very large amount of data that must be properly 
analyzed and interpreted.
FCM methodology is increasingly used as a detection method for antigens using the particle immuno-
assay (PIA). In the first step, magnetic particles of µm dimensions are coated with one or more differing 
antibodies. The particles are incubated with the analyte, containing the respective antigen. Using antibody/
antigen-specific fluorescent labels, those particles carrying a specific antigen can be identified by FCM. Using 
different particle sizes and different fluorescent labels with characteristic fluorescence emission peaks, some 
100 antigens can be determined in a single run. This is a novel approach for multiplexed analysis of a large set 
of disease markers in a single patient, and the FCM technique is becoming an increasingly important method 





in newly formed DNA
Add labeled
BrdU*
BrdU* = fluorescence-labeled 5-Bromo-2′-deoxyuridine
Antigen-specific T-cell receptor (TCR)
T-lymphocyte
BrdU*
Fig. 10 Lymphocyte transformation test (LTT). This test is used to find out whether the lymphocytes of a patient with a type 4 
allergy are reactive to the suspected antigen (e.g., a drug or metal). Lymphocytes are taken from the patient’s blood, exposed 
to the suspected antigen, then allowed to grow in culture in the presence of an indicator for DNA replication (here labelled 
5-bromo-2′-deoxyuridine, BrdU) for a couple of days. Antigen-sensitized cells will be induced by the antigen to proliferate 
(divide). The extent of proliferation is indicated by the amount of BrdU that is incorporated in DNA.
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patient’s immune status [130]. It allows discovery of changes in cell physiology (e.g., in combination with 
microscopic screening [131, 132]), and also screening for bacteria [133] or enzyme activities [134]. A limitation 
is the high cost of these advanced instruments and the fact that they require a highly trained operator and 
strict laboratory conditions. Adequate quality control is obviously essential [135].
Apart from its diagnostic power, FCM technology is also capable of sorting and separating cells according 
to their features in a method called fluorescence-activated cell sorting (FACS). Each fluorescence signal trig-
gers a shutter, by which the different subtypes of cells can be separated and enriched.
In magnetic cell separation, surface antigens are labelled with antibody conjugates that are attached to 
magnetic nanospheres. Cell types can then be separated according to their labels by use of a magnetic field.
8  Progress and limitations in applied immunodiagnostics
8.1  Types of samples and matrices
Immunochemistry is a highly dynamic field. Its rapid development is often in competition with that of 
instrumental analytics, and sometimes in cooperation with it. In both areas, there are similar attempts to 
miniaturize the devices and speed up analysis time. The application areas are expanding, and the need for 
multiplexed and high-throughput solutions is evident [136–140]. The term “immunochemistry” was intro-
duced about 100  years ago in connection with observations in the blood [141], and until recently, immu-
nochemical applications mainly dealt with antigens and antibodies in the blood and other body fluids. 
These serological examinations were directly health-related. In the past decade, immunochemical analyses 
have increasingly expanded and included extracorporeal agents, such as food residues and environmental 




















Fig. 11 Flow cytometry. Flow cytometry is classically used to identify lymphocyte subpopulations in blood, but can also be used 
for other cell types, bacteria, or microparticles. Fluorescence-labelled antibodies that are specific to surface molecules of a 
cellular subtype are added to the cell mixture. The cell suspension is then moved through an optical device, where fluorescence 
emission and light scatter is measured of each cell. This gives information about the size and subtype of each cell. Cells can 
also be sorted according to their features.
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applications can be considered indirectly health-related. In the following section, major immunochemical 
application fields are described.
8.2  Investigation of physiological regulation processes
In the healthy state of an organism, biochemical parameters in blood and urine tend to stay within relative 
small concentration limits (homeostasis). When the balance is disturbed, additional regulatory processes 
come into play. An example is cytokine release from cells of the immune system as a consequence of immu-
nological defence mechanisms. The release from cells can be measured by ELISPOT and the concentrations 
in blood by ELISA. The relative concentrations of different cytokines reflect a certain regulatory status of the 
immune system and are used for the understanding of their role in inflammatory disease [142, 143]. Since 
increasingly more test reagents are available for the different cytokines and their receptors, such approaches 
contribute to a better understanding of the events during immune response in health and disease.
Another example is that of phosphorylated proteins. Phosphorylated proteins and their unphosphoryl-
ated counterparts play a key role in cellular regulation, but their differential measurement with traditional 
biochemical methods is difficult and not suited for routine implementation. The development of separate 
antibodies against unphosphorylated proteins and their various phosphorylated forms will give more insight 
into normal regulation and deviations in disease [144, 145].
One of the best-known examples for the measurement of hormonal upregulation is the pregnancy test. 
It measures the level of human chorionic gonadotropin in the urine, which is elevated in pregnancy [146]. As 
noted above, the lateral flow pregnancy test is one of the most used point-of care-tests today. It can be per-
formed by anybody and delivers reliable and accurate results [5].
8.3  Drug monitoring
Some pharmaceutical drugs, such as cyclosporin A or digoxin, have a very narrow therapeutic range between 
ineffective low dosing and toxic overdosing, especially if patients have an unusual elimination (e.g., due to 
kidney disease). In such cases, drug monitoring is important. Classically, this is done by analytical chemical 
methods. However, these require a specialized laboratory and personnel. For routine diagnosis, immuno-
chemical assays make it easy to monitor the levels of therapeutic drugs, but also addictive drugs in suspected 
persons or in persons participating in a withdrawal program. Although a urine sample [147] can provide the 
result within minutes, a possible interference from other pharmaceutical drugs may lead to incorrect results 
[148, 149].
Table 2 Matrices and analytes for which immunochemical analysis is increasingly applied (examples).
Matrix   Analytes
Blood   Disease markers, drugs, autoantibodies
Tissue sample   Organ structure, cell structure, cancer diagnosis
Biotechnology sample   Antigen and/or antibody
Soil   Environmental chemicals, microorganisms
Air   Allergens, workplace chemicals
Drinking water   Organic contaminants
Open waters   Microorganisms, toxins, contaminants
Food   Biocide residues, contaminants, additives
Dust   Allergens, environmental chemicals
The table gives an overview on the different fields in which immunochemical assays are applied. While in its beginning, immuno-
chemical analysis was confined to blood components, the number of application fields has meanwhile rapidly increased.
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8.4  Organ disease markers
Hundreds of disease markers are measured in the daily routine of the clinical laboratory. Some of the more 
traditional disease markers are enzymes that are released from an injured organ, such as α-amylase from 
injured pancreas or γ-glutamyl-transpeptidase from damaged liver. Such enzymes then circulate in the blood 
and can be measured in a serum sample by studying the conversion of their substrate to the product. However, 
in some cases there are several isoenzymes released from different organs, which will all contribute to the 
enzymatic turnover. Lactate dehydrogenase is a prime example. In such cases, the use of selective immunoas-
says for each of the isoenzymes is a very reasonable diagnostic approach to identify the injured organ. There 
are also nonenzymatic disease markers, such as troponin, which is released from cardiac cells during a heart 
attack [150]. This is measured by sensitive immunochemical methods.
The hormone insulin was one of the first analytes for which an immunoassay was used [1]. Insulin meas-
urement has since been important for diabetes research, but less for routine diagnosis of diabetes. Due to 
the development of more sensitive immunochemical methods [151] and the trend towards very small blood 
volumes (e.g., from children) [152] insulin measurement may play a more prominent role in individualized 
medicine either to monitor endogenous insulin levels or to control the levels of therapeutic insulin [46]. 
Steroid hormones such as progesterone [153] are also typically measured with sensitive immunoassays.
8.5  Markers for autoimmune disease
One can generalize that those cells of the immune system that are directed towards foreign molecules are 
encouraged to proliferate, whereas cells directed towards “self” molecules of the body will be destroyed. 
The latter results in “immunological tolerance”. The system is efficient but not perfect. As a consequence 
of disturbance of the self-tolerance mechanisms, the immune system may treat self-molecules as if they 
were foreign, causing immune reactions that result in autoimmune disease [154–156]. This is often directed 
towards only one or a few types of molecules of just one organ. Clinically, it is accompanied by settlement 
of inflammatory cells in that tissue and gradual loss of organ function [157, 158]. Rheumatoid arthritis and 
Hashimoto thyroiditis are common examples of autoimmune diseases. Immunohistochemical methods to 
detect antigens in tissues combined with immunoassays to detect the autoantibodies have led to a continu-
ous improvement in diagnosis [159, 160].
Celiac disease is an example of a quite common intestinal disease that was widely undiagnosed until 
recent dramatic improvements in immunodiagnostic markers [161–164]. Celiac disease is a hypersensitivity 
to the wheat protein gluten. It is a disorder where allergic and autoimmune reactions are both involved. The 
availability of potent tests to measure IgA autoantibodies against tissue transglutaminase or endomysium 
of connective tissue, and antibodies against the wheat protein gliadin is a great diagnostic advance and will 
probably replace the invasive duodenal biopsy as a standard for diagnosis.
Some further examples of development of potent disease markers are autoimmune hepatitis [165], auto-
immune urticaria [166], protective autoimmunity in cancer [167], and autoimmune lymphoproliferative syn-
drome [168].
8.6  Markers for allergic disease
In general, four types of allergies can be differentiated based on their immune mechanisms. All four involve 
a hyper-reactivity of the immune systems, although the mechanisms and symptoms are very different. Immu-
nodiagnostic approaches are important for all four. As an example, type 1 allergy is caused when foreign 
substances, notably proteins (like grass pollen proteins) get in contact with mucosal surfaces such as the 
respiratory and gastrointestinal tracts and are recognized by the immune system as antigens. After the first 
exposure and a lag time, the immune system starts to produce antibodies of the IgE type. The antibodies 
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circulate and bind to the histamine-storing mast cells in the mucous membranes and to histiocytes in the 
blood. Upon subsequent exposures, the antigen will bind to its IgE and thus evoke an explosive histamine 
release from the histamine-storing cells. Released histamine is a hormone-like mediator that causes the 
known symptoms of type 1 allergies, characterized by local edema, pain, and inflammation, and after enter-
ing the circulation, lowering of blood pressure. Diagnostic tools for a type 1 allergy are the skin prick test, 
the oral food challenge test, and immunodiagnostic measurement of allergen-specific IgE in the blood [169]. 
High-specific IgE levels are associated with a higher risk for an allergy. Immunodiagnostic tests are also used 
to identify the triggering antigen in the environment (e.g., house dust mite proteins, cat hair, mould compo-
nents, grass pollen, latex proteins, etc.).
The steadily improving and expanding diagnostic possibilities are very helpful for patients. However, 
some offered allergy tests measure immunological parameters that have not been proven to be associated 
with disease. An example is the measurement of IgG4 antibodies in connection with food intolerances [169]. 
Although it is known that positive results are not correlated with clinical symptoms, such an incorrect inter-
pretation is quite common, and may give the patient a false belief that he/she has to avoid essential nutrients, 
with the consequence that a normal life becomes almost impossible.
Type 4 allergies are often triggered by small molecules such as metal compounds or drugs, which act 
as haptens to which T cells become sensitized. When there is a suspicion for a metal or drug allergy that 
would often be expressed as a skin rash, the causative agent may be detected with the help of a T-cell spe-
cific test. The patient’s T cells are isolated and exposed to suspected antigens. Sensitized T cells may show 
increased reactivity to an allergen or its peptides that can be measured either by detecting cytokine release 
using ELISPOT [170] or by the proliferation of lymphocytes in the LTT [127], see above.
8.7  Cancer markers
Cancer cells are characterized among others by a change in protein expression. The appearance of fetal pro-
teins or non-organ specific proteins, as well as an uncharacteristic distribution of proteins, is quite common. 
Moreover, previously sequestered proteins may present to the immune system and may induce the forma-
tion of tumour-specific autoantibodies. Atypical, tumour-specific proteins may be detectable in biopsies with 
immunohistochemical methods, or may be detectable following release into the blood [171, 172]. The increas-
ing availability of such tumour markers and their antibodies has supported the idea that many tumour types 
occur in subtypes. These can be differentiated with immunochemical methods and will increasingly be the 
basis for individualized treatment.
Not all the known tumour markers fulfil the promise of specific and sensitive diagnostic utility [173]. An 
example is prostate-specific antigen (PSA). Serum of men with healthy prostates contains small quantities of 
PSA. Elevated PSA is often associated with prostate cancer and other prostate disorders [174]. It was believed 
that PSA should be used to monitor middle-aged men for a possible prostate tumour, but it has become 
evident that PSA measurement is associated with false positives and therefore unnecessary treatment [175]. 
The U.S. Preventive Services Task Force (USPSTF) recommends that “for men of any age…doctors and patients 
do not screen for prostate cancer because the potential benefits do not outweigh the harms” [174]. Neverthe-
less, PSA still has its role as parameter, for example, for monitoring progress during treatment.
Carcinoembryonic antigen (CEA) is a glycoprotein normally found in the embryo. In adults, its presence 
is associated with cancers such as lung tumours. Its blood level can be used as an indicator for the activity of 
a malignacy. There are efforts to further improve the immunoassays and immunohistochemical tests for CEA 
[176]. Some further examples are:
 – carcinoembryonic antigen in lung cancer [177]
 – tumour markers [178]
 – gynecological cancer [179]
 – pancreatic cancer [180]
 – breast cancer [181, 182]
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 – breast cancer differential diagnosis [183]
 – undifferentiated tumours [184], leukemias [185, 186], and soft-tissue tumours [187]
 – renal neoplasms [188]
 – oral cancer [189]
8.8  Markers for infectious diseases
Recent advances in the immunodiagnosis of infectious diseases have been discussed in several review arti-
cles [190–192]. The classical method for identification of bacteria is their isolation and growth on selective 
culture media. Final detection is usually performed by staining, microscopy, biochemical assays, and immu-
nochemical procedures. In recent years, these classical identification methods have been supplemented and 
sometimes replaced by the advent of genetic fingerprinting with polymerase-chain reactions [193].
However, another strong detection strategy is based on the concept that intruding infectious microorgan-
isms usually lead to reactions of the immune system, resulting in the production of specific antibodies. These 
can be measured in the blood. Such antibodies are studied in immunoassays with the aid of suitable anti-
gens that have previously been isolated from the cultured pathogenic microorganisms. Positive findings can 
prove that an infection has taken place even when the infectious agent cannot be detected. The relative time 
courses and levels of specific IgM and IgG antibodies in the blood provide information about the onset and 
intensity of the infection. The combined serological results often give reasonable information for the further 
treatment of a patient. Good examples are hepatitis C [194] and HIV diagnosis [195]. The methods to study 
disease subtypes and their association with therapeutic success have been improved. It is hoped that there 
will also be a shift towards point-of-care diagnostics. Rapid tests are required especially for diagnosis in rural 
areas with poor medical infrastructure, for example, to diagnose tropical diseases [8]. Instantaneous on-site 
results are also valuable in clinical settings, because they allow treatment of bacterial infections with micro-
organism-specific antibiotics from the time of diagnosis. Moreover, there is a great need for immunoassays 
to detect parasitic diseases, such as malaria [196]. The problem is that the immune system does not readily 
develop antibodies against parasites, and, despite many efforts, the quality of available immunoassays is 
often insufficient. Nonetheless, given the immense interest and investments in immunochemical research in 
the past decade, we will certainly see suitable solutions in the future.
8.9  Markers in food hygiene
Food regulations are monitored by industrial and public food chemists. While some time ago only a few 
parameters, such as the visual detection of parasites in meat, were monitored, today the spectrum has 
expanded immensely. The newer analytes include natural ingredients, chemical residues, additives, micro-
bial contaminations, parasites, and others. The increasing number of parameters would overcome the capac-
ity of the controlling agencies, unless the classical methods were replaced by multiplexed, high-throughput 
methods. Therefore, there is a natural pressure for developments in this direction. An example for the advan-
tage of immunoassays in this field is the monitoring of botulinum toxin in food, previously studied with a 
mouse bioassay, which can now be detected with a lateral flow device as an alternative [197].
Further examples of surveying for infectious agents, residues and contaminants are:
 – pathogenic microorganisms on food [198]
 – Staphylococcal enterotoxin B in milk [199]
 – pesticides in fruits [200] and rice [201]
 – human exposure to pyrethroid pesticides [202]
 – melamine in milk [203]
 – antibiotics in milk [204]
 – wheat proteins in milk powder [205]
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8.10  Markers for environmental chemical exposure
Monitoring environmental media such as air, soil, and water is a key activity that has contributed to 
the successful sanitation of environmental media in many countries in the past 30 years. Meanwhile, 
methods in analytical chemistry have improved beyond expectations. Hand-held analytical devices 
help to monitor and reduce levels of toxic chemicals at the work place. GC and GC-MS have been devel-
oped to an unexpectedly high sensitivity. Instrumental analytical methods will always be required as a 
final proof for identification but such instruments require intense maintenance and highly specialized 
operators, and may be quite costly. This is one reason for the development of immunoassays even for 
such chemicals, despite the existing, sensitive, and accurate instrumental analysis. Immunochemical 
methods make it possible for contaminants to be measured with less sophisticated equipment by less-
skilled workers at lower cost in less time. Immunoassays have been developed for environmental con-
taminants such as 1,1,1-trichlor-2,2-bis-(4-chlorophenyl)ethan (DDT), 2,3,4,5,6-pentachlorophenol (PCP), 
polychlorinated biphenyls (PCBs), polycyclic aromatic hydrocarbons (PAHs), and many other chemical 
families.
When using such immunochemical assays, one must be aware that the results will not be identical with 
those of GC-MS; one cannot expect that the antibodies (e.g., for polychlorinated dibenzodioxins) will react 
with each congener proportionally to their mass concentration in the sample, and this has to be taken into 
account when interpreting the results. Some examples of applications involving small and environmentally 
important toxic substances are:
 – cadmium [206]
 – PAHs, PCBs [207], dioxins [208]
 – organophosphorus pesticides [209, 210]
 – pyrethroid pesticides in water [211]
 – mycotoxins [212] and bacterial toxins [213]
 – the wood preservative pentachlorphenol (PCP) in soil [214]
 – explosives [215]
 – chemical warfare agents [216]
8.11  Examples from veterinary medicine
Notably in farm animals, the monitoring of animal health and prevention of infectious disease is of major 
importance. Although the primary responsibility for hygiene lies with the owner, animal health and avoid-
ance of infectious disease is of public interest. The veterinarian should have analytical tools available that 
provide rapid, reliable information on the presence of diseased animals on a farm. Immunochemical assays 
will thus increasingly be used as point-of-care diagnostic systems. The test systems are similar to those we 
know from human applications for studying infections, organ disease, reduced growth, or residues of envi-
ronmental contaminants or pharmacological agents in animals. Beyond that, species-specific diseases such 
as bovine mastitis must be monitored, where ELISA can be used for early diagnosis [217]. One of the most 
recent and commercially available examples is a microfluidic sedimentation cytometer for milk quality and 
bovine mastitis monitoring, reported by Garcia-Cordero et al. [218]. Their detection system consists of 12 inde-
pendent microfluidic devices, essentially flattened funnel structures, fabricated on the footprint of a single 
plastic compact disc (CD). Their device features rapid, low-cost, portable microfluidic sedimentation cytom-
eter (SeCy) for assessing the somatic cell count and fat content of milk in 15 minutes using a “sample-in, 
answer-out” approach. Apart from bovine mastitis, it is also important to measure Staphylococcal enterotoxin 
in milk [24] to survey possible infections of cows.
The use of growth hormones to increase the yield of milk in dairy cattle has been widely banned. Methods 
are required to survey compliance with this ban and have been developed, for example, to detect insulin-like 
growth factor in cattle [219].
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8.12  Limits and problems of interpretation
Each immunochemical diagnostic method requires a specific strategy that allows for pre-separation of matrix 
components and interfering substances so that the antibody–antigen reaction and detection will take place 
in a clean environment. To exclude the possibility of false results due to impurities, cross-reactions, or unsuit-
able analyte concentrations, it is necessary to run intra-lab quality controls and if available also inter-lab 
controls [135, 220]. Moreover, any new immunochemical test should prove its suitability in comparison with 
other analytical methods.
Immunoassays are developed to measure the analyte at low concentrations with high specificity and 
accuracy. One might therefore assume that from the point of view of clinical chemistry, results will always be 
clear and correct. However, immunoassays are complex constructs. Unless the prescribed reaction conditions 
are carefully followed, there is a danger of false results. Another and perhaps even more relevant problem is 
that of interpretation of the results. Many tests measure specific parameters with good sensitivity and accu-
racy. Nevertheless, there are cases where the results are of little or no diagnostic value. An example is the 
IgG4 measurement in connection with food allergies mentioned above. Despite some tests showing elevated 
levels of IgG4 antibodies, this is not a reliable indication of a food allergy. Relying on this kind of test, thou-
sands of patients have been warned not to eat food for which they were tested positive, albeit the test has no 
reasonable predicative relevance. Another example is PSA, which for many years has been proposed as a pre-
dictive marker to survey for possible prostate cancer, but now the recommendation is changing [174]. While 
measurement of a diagnostic parameter must always have a rationale and validation, the extreme sensitivity 
of immunologically based methods increases the potential for abuse. Thus, it is important for researchers to 
consider the limits of immunoassays [221].
9  Future developments
Health-related applications of immunological detection methods and immunosensors will continue to 
develop, and two developments in particular can be anticipated. Due to the improvement of immunosensor 
techniques one can expect that point-of-care diagnostics will expand, notably in areas with a weak medical 
infrastructure. On the other hand, the professional labs will be provided with high-throughput, multiplexed 
automated systems that can measure perhaps dozens of immunological parameters with high sensitivity and 
accuracy. In both areas, good quality control will remain the basis for correct results.
10  List of abbreviations
CCD  charged coupled device
CD  cluster of differentiation
cDNA  complementary DNA strain
CDRs  complementarity-determining region
CEA  carcinoembryonic antigen
ChIP  chromatin immunoprecipitation
CMOS  complementary metal oxide semiconductor
CSA  catalyzed signal amplification
DDT  1,1,1-trichlor-2,2-bis-(4-chlorophenyl)ethan (insecticide)
EIA  enzyme immunoassay
ELISA  enzyme-linked immunosorbent assay
ELISPOT enzyme-linked immunospot assay
Fab  antigen-binding fragment
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FACS  fluorescence-activated cell sorting
Fc  constant fragment of antibody
FCM  flow cytometry
FLISA  fluorescence-linked immunosorbent assay
Fv  variable fragment of antibody
HIV  human immunodeficiency virus
HRP  horseradish peroxidase
IDA  iminodiacetic acid
IgG  immunoglobulin G (a major class of antibody)
IPCR  immuno-polymerase chain reaction
LOCI  luminescent oxygen channelling immunoassay
LTT  lymphocyte transformation test
NP  nanoparticle
NTA  nitrilotriacetic acid
PAH  polycyclic aromatic hydrocarbon
PCB  polychlorinated biphenyl
PCP  2,3,4,5,6-pentachlorophenol (pesticide)
PSA  prostate-specific antigen
RIA  radioimmunoassay
SABC  streptavidin-biotin complex
SAF  supercritical angle fluorescence
SAM  self-assembled monolayer
scFv  single-chain variable fragment
sdAb  single domain antibody
SeCy  sedimentation cytometer
SPR  surface plasmon resonance
TCR  T-cell receptor
TIRE  total internal reflection ellipsometry
VHH  variable domains of the heavy chain of llama heavy-chain antibodies
11  Glossary
A full glossary of terms can be found in [222].
12  Membership of sponsoring body
Membership of the IUPAC Chemistry and Human Health Division Committee for the period 2014–2015 is as 
follows:
President: T. J. Perun (USA); Vice President: R. Cornelis (Belgium); Secretary: M. Schwenk (Germany); 
Titular Members: E. Differding (Belgium); J. Fischer (Hungary); V. Gubala (Slovakia); P. Illing (UK); L. John-
ston (Canada); H. Møller Johannessen (Denmark); W. A. Temple (New Zealand); Associate Members: Vincenzo 
Abbate (UK); M. Kiilunen (Finland); Y. C. Martin (USA); S. Mignani (France); D. Rotella (USA); National Rep-
resentatives: N. Nahar (Bangladesh); M.-X. Wang (China/Beijing); R. Jih-Ru Hwu (China/Taipei); S. Alihodžić 
(Croatia); A. Rahatgoanker (India); G. Bee Teh (Malaysia); R. Leurs (Netherlands); B. Haug (Norway); S. 
Bachurin (Russia); P. Ploypradith (Thailand).
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